Two stock leaders with the potential to outperform the market by 2030

Investing in stock markets can be erratic, but a long-term horizon brings a higher probability of interesting returns. Many investors opt for index funds tracking the S&P 500, but those seeking higher appreciation can focus on specific companies with the potential to outperform the market.

Analysts therefore highlight the qualities of two stocks that may outperform the market by 2030. Which stocks are they?

Amgen - a strong pharmaceutical company with a growing dividend

Amgen $AMGN is one of the leading pharmaceutical companies and its growth potential is significant. Key products in its portfolio are Tezspire, a treatment for asthma, and Tepezza, for the treatment of eye disease associated with thyroid disorders. In addition, Tezspire is undergoing further clinical trials and has the potential to expand its approved indications.

Amgen is also expanding in the treatment of obesity, which is currently one of the fastest growing segments of the pharmaceutical market. Its promising candidate MariTide could compete with the current leaders in this area. Another interesting project is rocatinlimab, an eczema drug that has produced encouraging results in recent clinical trials.

Financially, Amgen boasts solid growth. In 2024, its revenues grew by 19% In addition to a strong product line, Amgen is attractive to dividend investors. The current dividend yield is approximately 3%which is higher than the average of the S&P 500 (1.3%). Finally, over the last ten years, Amgen has increased its dividend by 201 %.

Intuitive Surgical - a leader in robotic surgery

Intuitive Surgical $ISRG has dominated the robotic surgery market for over 20 years with its da Vinci Surgical System. The latest version of da Vinci 5, which received FDA approval in 2024, delivers significant improvements, including increased accuracy and ten times the computing power of the previous generation. A unique feature is Force Feedback, which helps surgeons control tissue pressure more precisely, reducing the risk of patient harm.

These innovations are helping the company grow - in the fourth quarter of 2024, it sold 493 da Vinci Surgical Systemsof which 174 were the latest generation. Revenues in the same period grew year-on-year by 25 % to $2.41 billion, and adjusted earnings per share increased from $1.60 to $2.21.

Intuitive Surgical also benefited from growing surgical volumes. Over the past five years, the number of surgeries performed using da Vinci systems has grown at a rate 17% per year.. Since 2000, when the first system was approved, Intuitive has treated 16 million patientswhile 10 million in the last five years alone..

With the new da Vinci 5 system and its innovations, further expansion can be expected, making Intuitive Surgical one of the most promising growth stocks.

Disclaimer: There is a lot of inspiration to be found on Bulios, but stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.

Source: TheMotleyFool